Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
34.8
74.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co Ltd
Research & Development
Suzhou Zelgen Biopharmaceuticals Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
|
Research & Development
-¥458.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Research & Development
-¥12.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Research & Development
-¥1.1B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Research & Development
-¥192.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Research & Development
-¥992.9m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Research & Development
-¥232.4m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
Suzhou Zelgen Biopharmaceuticals Co Ltd
Glance View
Suzhou Zelgen Biopharmaceuticals Co., Ltd. engages in the innovation, research, development, manufacturing, and commercialization of new medications. The company is headquartered in Suzhou, Jiangsu and currently employs 688 full-time employees. The company went IPO on 2020-01-23. The firm's main technology platforms include precision small molecule drugs R & D and industrialization platform and complex recombinant protein drug development and industrialization platform. The firm's R & D product pipelines include Donafenib, Recombinant human thrombin for topical use, Jaktinib hydrochloride tablets, Alkotinib, Recombinant human thyroid stimulating hormone for injection, Jaktinib hydrochloride cream, ZG5266, ZG0588, ZG170607, double Specific antibodies ZG005 and ZG006. The firm also provides R & D and clinical trial drug production and processing services. The firm operates its businesses primarily in Mainland China.
See Also
What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Research & Development?
Research & Development
-458.9m
CNY
Based on the financial report for Dec 31, 2023, Suzhou Zelgen Biopharmaceuticals Co Ltd's Research & Development amounts to -458.9m CNY.
What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-29%
Over the last year, the Research & Development growth was 0%. The average annual Research & Development growth rates for Suzhou Zelgen Biopharmaceuticals Co Ltd have been -19% over the past three years , -29% over the past five years .
You don't have any saved screeners yet
